166 related articles for article (PubMed ID: 37045502)
41. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
42. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
43. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
[TBL] [Abstract][Full Text] [Related]
45. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
[TBL] [Abstract][Full Text] [Related]
46. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
47. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
48. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
[TBL] [Abstract][Full Text] [Related]
49. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
[TBL] [Abstract][Full Text] [Related]
50. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
[TBL] [Abstract][Full Text] [Related]
51. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK
Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827
[TBL] [Abstract][Full Text] [Related]
52. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
53. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Xi Z; Fang F; Wang J; AlHelal J; Zhou Y; Liu W
Platelets; 2019; 30(2):229-240. PubMed ID: 29257922
[TBL] [Abstract][Full Text] [Related]
54. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
[TBL] [Abstract][Full Text] [Related]
55. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
[TBL] [Abstract][Full Text] [Related]
56. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of Clopidogrel vs Alternative P2Y
Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Ortega-Paz L; Gong Y; Kerensky RA; Kulick N; McDonough CW; Nguyen AB; Wang Y; Winget M; Yang WE; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Lee CR; Cavallari LH
J Am Coll Cardiol; 2024 Apr; 83(15):1370-1381. PubMed ID: 38599713
[TBL] [Abstract][Full Text] [Related]
58. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
[TBL] [Abstract][Full Text] [Related]
59. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
[TBL] [Abstract][Full Text] [Related]
60. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
